sumatriptan has been researched along with Trigeminal Autonomic Cephalalgias in 6 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Trigeminal Autonomic Cephalalgias: Primary headache disorders that show symptoms caused by the activation of the AUTONOMIC NERVOUS SYSTEM of the TRIGEMINAL NERVE. These autonomic features include redness and tearing of the EYE, nasal congestion or discharge, facial SWEATING and other symptoms. Most subgroups show unilateral cranial PAIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The TACs include cluster headache, paroxysmal hemicrania, and short-lasting neuralgiform headache attacks with conjunctival injection and tearing; hemicrania continua, although classified separately by the International Headache Society, shares many features of both migraine and the TACs." | 2.49 | Primary headache disorders. ( Benoliel, R; Eliav, E, 2013) |
| "The group includes cluster headache (CH), paroxysmal hemicrania (PH), and short-lasting neuralgiform headache with conjunctival injection and tearing (SUNCT)." | 2.44 | [Trigeminal autonomic cephalgias: diagnostic and therapeutic implications]. ( Rosenberg-Nordmann, M; Sprenger, T; Tölle, TR, 2007) |
| "TACs include cluster headache (CH), paroxysmal hemicrania (PH) and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT syndrome)." | 2.44 | [Pathophysiology and treatment of trigeminal autonomic cephalalgias]. ( Cohen, AS; Goadsby, PJ, 2008) |
| "For the acute treatment of cluster headache attacks, oxygen (100%) with a flow of at least 7 l/min over 15 min and 6 mg subcutaneous sumatriptan are drugs of first choice." | 2.43 | EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. ( Afra, J; Evers, S; Goadsby, PJ; Leone, M; Linde, M; May, A; Sándor, PS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benoliel, R | 1 |
| Eliav, E | 1 |
| Pareja, JA | 1 |
| Álvarez, M | 1 |
| May, A | 1 |
| Leone, M | 1 |
| Afra, J | 1 |
| Linde, M | 1 |
| Sándor, PS | 1 |
| Evers, S | 1 |
| Goadsby, PJ | 2 |
| Rosenberg-Nordmann, M | 1 |
| Tölle, TR | 1 |
| Sprenger, T | 1 |
| Cohen, AS | 1 |
| Kozminski, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
5 reviews available for sumatriptan and Trigeminal Autonomic Cephalalgias
| Article | Year |
|---|---|
Primary headache disorders.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anticonvulsants; Chronic Disease; Cluster Headache; Cycloox | 2013 |
The usual treatment of trigeminal autonomic cephalalgias.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2013 |
EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias.
Topics: Advisory Committees; Analgesics; Clinical Trials as Topic; Cluster Headache; Europe; Humans; Lithium | 2006 |
[Trigeminal autonomic cephalgias: diagnostic and therapeutic implications].
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Cluster Headac | 2007 |
[Pathophysiology and treatment of trigeminal autonomic cephalalgias].
Topics: Administration, Oral; Amines; Analgesics; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroida | 2008 |
1 other study available for sumatriptan and Trigeminal Autonomic Cephalalgias
| Article | Year |
|---|---|
Resident and fellow section. Expert opinion: trigeminal autonomic cephalgia post transsphenoidal surgery.
Topics: Adenoma; Adrenal Insufficiency; Adult; Analgesics; Anticonvulsants; Carbamazepine; Diabetes Insipidu | 2008 |